We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

GlaxoSmithKline plc, Aviva plc And Ryanair plc: 3 Shares To Buy Now

GlaxoSmithKline plc (LON: GSK), Aviva plc (LON: AV) and Ryanair plc (LON: RYA) are three shares to add to your Lifetime ISA.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I think George Osborne has delivered a great budget for investors. With him increasing the ISA allowance from £15,240 to £20,000 (as from April 2017), and cutting capital gains tax, it all means that investors will now have to pay far less tax on their shareholdings and that can only encourage investment.

And the fact that tax on buy-to-let has been increased makes buying stocks an even more attractive option for those who want to make the most of their savings. That’s why there has been no better time to start investing. And if you want to buy into the stock market, here are my three shares to start with right now.

XXX

GlaxoSmithKline

Big Pharma has tended to disappoint in recent years, as the patent cliff and increasing competition from generics has led to stagnant profits. Yet there’s no doubt that there’s an increasing market for medicines, as the world’s population increases, as it ages, as it gets more wealthy, and as the demand for treatments for ‘rich man’s’ diseases such as cancer, heart disease and diabetes grows.

The science base in this country, from large companies and SMEs to the universities, is one of the strongest in the world. GlaxoSmithKline (LSE: GSK) can feed off these many strengths to develop and market its treatments for a global marketplace. And it’s working towards this by expanding beyond the chemical drugs of the past into biotechnology, vaccines, consumer healthcare and HIV treatments.

With this potential in mind, a 2016 P/E ratio of 16.34 seems reasonable, and a dividend yield of 5.77% is appealing. Buy this for the income and for its long-term growth prospects.

Aviva

Insurance may not be a glamorous industry, but for investors in search of blue-chip income and growth, this has been a happy hunting ground. Global insurer Aviva (LSE: AV) is a case in point.

After going through a rocky patch in the years following the Credit Crunch, during which time the bloated insurance giant turned a loss and had to slash jobs, Aviva is now strongly profitable again. And it’s also yielding an impressive dividend. A 2016 P/E ratio of 10.50, and a 5.28% dividend yield make Aviva a strong buy, in my opinion.

Ryanair

Amidst the commodities crunch, with oil and mineral prices collapsing, and the shares prices of firms such as BP and BHP Billiton falling, one group of companies has (perhaps not surprisingly) emerged as winners from the turmoil: the airlines.

One airline that’s frequently overlooked as an investment is Ryanair (LSE: RYA). This company flies budget routes all across Europe, and is already benefitting from falling aviation fuel prices. Earnings per share have jumped from 39.47p in 2013 to 62.68p in 2015, and are expected to climb higher still. And a 2016 P/E ratio of 14.67 looks good value too.

Prabhat Sakya has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Friends and sisters exploring the outdoors together in Cornwall. They are standing with their arms around each other at the coast.
Investing Articles

£503 buys 14 shares in this FTSE 250 stock that returned 23.9% annually for the last 15 years

This FTSE 250 stock has averaged a huge return for 15 years. At today's price, £503 buys 14 shares. But…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

£1,000 buys 25 shares in this FTSE 100 stock that’s returned 29.2% annually for the last 10 years

This FTSE 100 mining stock has returned close to 30% a year for a decade. At 3,995p, £1,000 buys 25…

Read more »

Female student sitting at the steps and using laptop
Investing Articles

Down 47%, is this growth stock finally worth buying in May?

With a £288m order book and a hidden pipeline of defence and nuclear contracts, is this growth stock now too…

Read more »

House models and one with REIT - standing for real estate investment trust - written on it.
Investing Articles

2 REITs yielding 7%+ to consider for passive income in 2026

A REIT backed by the NHS and another backed by Tesco and Sainsbury's with both yielding 7%+. Here's why I'm…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

Just 97 shares of this UK dividend stock generate £238 in passive income

A 5.7% yield, £238 in passive income from just 97 shares, and one of the most divisive dividend stocks on…

Read more »

ISA coins
Investing Articles

£10,000 in an ISA generates a second income of…

The London Stock Exchange is home to some of the world's most generous dividends. But how big a second income…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

Expert recommendations: 2 top income stocks yielding 7%+!

With yields of 7.2% and 7.8% respectively, these two income stocks are catching the eyes of institutional analysts. Should investors…

Read more »

Illustration of flames over a black background
Investing Articles

3 top income-focused stocks to buy in May 2026, according to experts

Looking for a stock to buy for income in May 2026? Experts have flagged these three UK dividend shares as…

Read more »